MApK downstream targets MAPKAP kinases (MK) 2 and 3 are critical for the regulation of the macrophage response to LPS. The extents to which these two kinases act cooperatively and distinctly in regulating LPS-induced inflammatory cytokine expression are still unclear. To address this uncertainty, whole transcriptome analyses were performed using bone marrow-derived macrophages (BMDM) generated from MK2 −/− or MK2/3 −/− animals and their wild-type littermates. The results suggest that in BMDM, MK2 and MK3 not only cooperatively regulate the transcript expression of signaling intermediates, including IL-10, IL-19, CXCL2 and the IL-4 receptor (IL-4R)α subunit, they also exert distinct regulatory effects on the expression of specific transcripts. Based on the differential regulation of gene expression by MK2 and MK3, at least six regulatory patterns were identified. Importantly, we confirmed our previous finding, which showed that in the absence of MK2, MK3 negatively regulates IFN-β. Moreover, this genome-wide analysis identified the regulation of Cr1A, NOD1 and Serpina3f as similar to that of IFN-β. In the absence of MK2, MK3 also delayed the nuclear translocation of NFκB by delaying the ubiquitination and subsequent degradation of IκBβ, reflecting the substantial plasticity of the response of BMDM to LPS.
It is becoming increasingly evident that in addition to being effector cells of the immune system, macrophages have vital homeostatic functions ranging from rather janitorial tasks, such as the clearance of cellular debris or the maintenance of erythrocyte turnover, to critical functions in wound healing, regeneration and tissue repair. This broad spectrum of activities is ensured by the notable plasticity that enables the physiology of these cells to be altered in response to environmental cues, producing different cell populations with distinct functions. To this end, macrophages are tightly interconnected with the surrounding cell populations via the controlled release and permanent sensing of intercellular communication signals. These signals include signaling peptides such as cytokines, chemokines, growth factors or arachidonic acid derivatives. In macrophages, at least in response to inflammatory pathogens, the expression of many of these mediators is controlled by the MAP kinase family member p38
MAPK and its downstream effector molecules. In addition to being critical for the initiation and establishment of the inflammatory response, this pathway is part of a signaling network that-in a cell type-dependent manner-modifies intracellular signal transduction and the cellular response towards cytokines such as IL-6 according to the context of coacting signals [1] [2] [3] [4] . In addition, the p38
MAPK pathway has been recently demonstrated to mediate not only the release of inflammatory mediators but also the type I interferon-dependent release of IL-10 and the subsequent prolonged activation of signal transducer and activator of transcription (STAT)3 2, 5, 6 . The latter protein is critical for the de-escalation and dissipation of the inflammatory response, indicating a key , it has been demonstrated that MK3 exerts negative regulatory effects on lipopolysaccharide (LPS)-inducible gene expression in the absence of MK2. In particular, IκBβ protein levels and NFκB activation in response to LPS stimulation, as well as IRF3 expression, appear to be affected if only MK3 is present 5 . Therefore, it is unclear to what degree the different IκBβ levels observable in macrophages deficient in MK2 alone or both MK2 and MK3 are due to reduced expression or enhanced degradation. Moreover, it is unknown, if these distinct regulatory effects of MK2 and MK3 described for the regulation of the IFN-β gene are true for LPS-inducible expression of only IFN-β or also of other genes. The present study aims to further characterize the differential impact of MK2 and MK3 on LPS-induced gene expression in macrophages.
Results
Deletion of MK2 or deletion of both MK2 and MK3 strongly alters gene expression in response to LPS. We previously demonstrated that in macrophages, the expression of the IL-10 gene in response to LPS requires MK2-mediated upregulation of IFN-β gene expression, activation of the IFN-α receptor (IFNAR) 1 and accumulation of the IL-10 transcript, which, in turn, is MK2/3-dependent 5 . Consistent with these findings, sustained IL-10 expression in response to LPS was significantly downregulated in primary bone marrow-derived macrophages (BMDM) that lacked MK2, an effect that -at least during early time points -tended to be enhanced upon the additional deletion of MK3 in MK2/3 −/− BMDM (Fig. 1a) . In contrast to this pattern but consistent with previous data from our group 5 , the induction of IFN-β expression, which, in contrast to that of IL-10, occurs rapidly and is short-term, was impaired in MK2 −/− macrophages and restored upon the additional deletion of MK3 (MK2/3 −/− ; Fig. 1b ) compared to that in wild-type control cells (wt BMDM). Notably, in macrophages that lack only MK3 (MK3 −/− BMDM), LPS-inducible expression of the IFN-β gene was not significantly affected (Supplemental Fig. S1b ), suggesting that MK3 only exerts its effects on the expression of genes such as IFN-β in the absence of MK2.
There seems to be a complex interplay between MK2 and MK3, wherein MK2 neutralizes the negative regulatory effects of MK3 on LPS-induced IFN-β gene expression. However, it is not clear whether this effect is limited to IFN-β or is generally applicable to additional target genes. To answer this question, gene expression in response to LPS treatment was analyzed via whole genome array analyses in BMDM prepared from the bone marrow of MK2 −/− and MK2/3 −/− animals as well as from the corresponding control animals after 2 and 6 h of treatment with 100 ng/ml LPS.
In this approach, the analysis was restricted to 33,325 out of 55,819 probes referring to genes related to NCBI listed accession numbers. Since several genes were proven by transcript expression with multiple probes, a total of www.nature.com/scientificreports www.nature.com/scientificreports/ 24,288 genes were included in the analysis. A response to LPS was considered relevant when the expression of the respective gene was significantly up-or downregulated, with a p-value of at least 0.05, upon treatment of the cells with LPS. Accordingly, after 2 h, a total of 11,768 genes and after 6 h, a total of 16,563 genes were significantly upor downregulated independent of the genotype. Next, these genes were separated by genotype, and the results are presented in Venn diagrams (Fig. 2a,b) . In wild-type macrophages, 6,580 transcripts (27% of the analyzed 24,288) exhibited a change in their expression after 2 h of treatment with 100 ng/ml LPS (Fig. 2a) , while in MK2 −/− and MK2/3 −/− macrophages, 8,264 (34%) and 8,982 (37%) of the genes, respectively, were influenced in response to LPS treatment. The overall number of genes responsive to LPS increased to 10,081 (42%) in wt BMDM and to 13,311 (55%) or 12,962 (53%) in MK2 −/− or MK2/3 −/− BMDM, respectively (Fig. 2b ), when stimulation with LPS was extended to 6 h.
Notably, after 120 min or 360 min of treatment, a group of 5,188 or 6,482 genes, respectively, became LPS-responsive, but this effect occurred only if either MK2 or both MK2 and MK3 were deleted. Hence, these data indicate that, in addition to being critical for the regulation of gene expression in macrophages in response to LPS, MK2 and/or MK3 are required to prevent a large number of genes from being regulated by LPS or from contributing to feedback regulation of the LPS response (Fig. 2a,b) .
Analysis of the differential regulation of LPS-inducible gene expression in macrophages by MK2 and/or MK3 reveals six different modes of regulation. Next, we aimed to focus on the LPS-responsive genes that were upregulated in wt BMDM and differentially regulated in the absence of either MK2 alone and/or both MK2 and MK3. Thus, the number of transcripts analyzed was restricted to those that were significantly upregulated in response to LPS in wt BMDM by at least four-fold. Of the 24,288 genes analyzed after 120 min of LPS treatment, 682 were identified to meet these criteria, and this number increased to 1,065 genes after 360 min of stimulation with LPS. Although in the analysis of the array data this upregulation was not significant, it was consistent with the RT-qPCR data outlined above (Fig. 1b) indicating that LPS-inducible transcript expression of the IFN-β gene is strongly diminished upon deletion of MK2 in MK2 −/− BMDM, whereas, compared to MK2 −/− BMDM, IFN-β gene expression significantly increases again upon additional deletion of MK3 in MK2/3 −/− BMDM and time dependently even exceeds that observed in wt BMDM. In addition, the expression levels of these genes compared to the wild-type control are listed in the Supplemental Fig. S2e1,f1 with the wild-type control defined as 100% and those genes mentioned in the following text are also presented as bar charts (Supplemental Fig. S2g-l S2h ). These genes are summarized as group I in Fig. 3a . As it was the case for the Ifnb1 gene, the regulatory pattern identified for the regulation of the Il10 gene was in line with the RT-qPCR data outlined above (Fig. 1a) and with previous observations from our group 5 . under wild-type conditions compared to that under MK2/3 double-deficient conditions. MK2 −/− vs. MK2/3
indicates the level under MK2-deficient conditions compared to that under MK2/3 double-deficient conditions. Therefore, the heat map color for each gene in each column reflects the degree of the difference between the expression levels of the respective genotypes. The red fields show enhanced expression in macrophages from the first listed genotype compared with the expression in the second genotype, whereas the blue fields show decreased expression in the first listed genotype compared with that in the second listed genotype. The white fields indicate no difference between the listed genotypes. Color transitions indicate patterns of differences in which at least one of the compared expression levels was significantly different (*p < 0.05; **p < 0.01; ***p < 0.001). ) mice and treated with 100 ng/ml LPS for the indicated time points. Total mRNA was extracted and analyzed using rtPCR as specified in the methods section. C1rA, Nod1 and Serpina3f are representative target genes of group III (a-c), whereas CXCL2, IL-4Rα and IL-19 are representatives of group I (d-f). Group II is represented by IL-12b (g), group IV by CXCL3 (h), group V by HDC (i) and group VI by CXCL9 (j). Data are presented as the means ± SEMs based on at least 3 replicates per condition. Statistics were calculated by 2-way ANOVA with the Bonferroni test. A p-value of less than 0.05 was considered significant. The following symbols indicate significance: *) wt vs. MK2 www.nature.com/scientificreports www.nature.com/scientificreports/ Based on these six groups defined on the basis of the distinct regulation of LPS-inducible gene expression by the protein kinases MK2 and MK3 (Figs 2c,d and S2a-d) the genes identified to be MK2-and/or MK2/3-dependently regulated by LPS were allocated to one of the six defined groups (Fig. 3a) : >or <20%). Using this approach the heatmap could be transformed into a map without any changes in the transition of color and assign a clear position for each gene within one of the six expression patterns (Supplemental Fig. S3a,b) . Based on this procedure, 31% of the 131 genes that were MK2-and/or MK2/3-dependently regulated after 2 h of LPS treatment, could be allocated to group II (Figs 3b and S4a) . Correspondingly, after 6 h of LPS treatment, 478 genes could be allocated to the six different expression patterns, with gene expression groups I and III as the biggest groups − 23% and 22%, respectively (Figs 3c and S4b) . Moreover, the proportion of LPS-inducible genes regulated by the interplay of MK2 and MK3 in the same way as Ifnb1 increased from 9% after 2 h to 22% after 6 h of LPS treatment.
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To demonstrate the relative strength of the influence of the respective knockout phenotype compared to the other genotypes on LPS-induced expression of the respective transcripts allocated to the six different groups in Fig. 3b,c , we further constructed a two-dimensional scatter plot (Fig. 3d,e) . Based on these analyses, genes representative of one of the six defined groups were selected to further validate and corroborate the different regulatory patterns characterizing the six different groups. As the original aim of the study was primarily to test the hypothesis that genes other than Ifnb1 are also similarly regulated by the interplay of MK2 and MK3, three genes -complement component 1 r subcomponent A (Cr1a), the inflammasome-component nucleotide-binding oligomerization domain-containing protein 1 (Nod1) and the serine peptidase inhibitor clade A member 3 F (Serpina3f) -were selected to further validate the regulatory pattern characteristic of group III. As demonstrated in Fig. 4a -c, LPS-inducible transcription of these three genes was reduced upon deletion of MK2 and, as is the case for IFN-β (Fig. 1b) , the additional deletion of MK3 in MK2/3 −/− BMDM resulted in at least partial reconstitution of the transcript levels compared to those in wt BMDM. Similarly, the chemokine CXCL2 (Cxcl2), the IL4 receptor (IL4R)α (Il4ra) and IL-19 (Il19) (Fig. 4d-f) were chosen as three genes that are regulated in a similar way as IL-10 (Il10) (Fig. 1a) and belong to the same group of genes (group I), which has been previously described as being either mainly MK2-dependently regulated or cooperatively regulated by MK2 and MK3. Additionally, based on the results shown in Fig. 3 for each of the other groups (II, IV, V and VI) defined in the present study, a representative gene was chosen, and its LPS-inducible expression was analyzed in wt BMDM, MK2
−/− BMDM and MK2/3 −/− BMDM using RT-qPCR for further validation. Consistent with the regulatory pattern described above for the genes summarized as group II, the LPS-induced accumulation of IL-12b transcripts was enhanced in MK2
−/− as well as in MK2/3 −/− BMDM compared to that in wt BMDM (Fig. 4g) , corroborating the assumption that the LPS-inducible expression of these genes is limited by either MK2 alone or by MK2 and MK3 in cooperation. In contrast, the transcript level of the chemokine CXCL3 (Cxcl3) was enhanced in MK2 −/− BMDM but not in MK2/3 −/− BMDM compared to that in wt BMDM (Fig. 4h) . Hence, as this gene is a member of group IV, its LPS-induced expression in BMDM lacking MK2 appears to be upregulated by MK3. In contrast, the transcript levels of genes such as HDC (Hdc) (group V) and CXCL9 (Cxcl9) (group VI) were either reduced (group V) or enhanced (group VI) in BMDM lacking both MK2 and MK3 (MK2/3 −/− BMDM) but not in wt BMDM or in MK2 −/− BMDM (Fig. 4i,j) . Notably, the LPS-inducible expression of none of the genes investigated in Fig. 1 (IL-10 and IFN-β) and Fig. 4 (Nod1, Cr1A, Serpina3f, CXCL2, IL-4Rα, IL-19, IL-12b, CXCL3, HDC and CXCL9) was significantly impaired in BMDM in which only MK3 was absent (Supplemental Figs S1 and S5). Hence, these data indicate that in the presence of MK2, the function of MK3 may be replaceable or compensated by another, yet unidentified, molecule or process.
As demonstrated recently for genes such as IL-10, tristetraprolin plays an important role in the regulation of genes summarized in group I. In addition to being regulated at the transcriptional level, the accumulation of IL-10 11-14 and CXCL2 9,11 transcripts is controlled at the level of mRNA stability. In this context, the mRNA binding factor tristetraprolin (TTP), which initiates mRNA degradation, is phosphorylated by MK2 and then disassociates from the target mRNA, leading to its stabilization 11, 13, [15] [16] [17] . Notably, the genes Cxcl1, Cxcl2 and Socs3 (Fig. 2c,d) , as well as Cebpd and Zfp36 (Supplemental Fig. S2 ), which were all defined as genes in group I (Supplemental Fig. S4 ), were also identified among the top 25 target genes of TTP reported in another array-based study 18 . Hence, it was conceivable that most of the group I genes are also targets of TTP, which was another common feature of the genes in this group. To investigate whether in addition to IL-10 and CXCL2, the IL-4Rα and IL-19 genes, which are representative members of group I, are also TTP target genes, we took advantage of immortalized TTP-deficient BMDM stably transfected with a vector encoding TTP or GFP under the control of a tetracycline-dependent promoter. In these cells, TTP expression can be reconstituted upon stimulation with doxycycline, allowing analysis of putative TTP target genes 19 . Notably, doxycycline-inducible TTP expression was further enhanced upon costimulation with LPS (Fig. 5a ). Consistently and in agreement with previous data, LPS-inducible IL-10 expression was substantially impaired upon reconstitution of TTP expression (Fig. 5b) . Similarly, upregulated transcript expression of the α subunit of the IL-4 receptor was significantly reduced in response to LPS, if TTP expression was coinduced (Fig. 5c ), indicating that its transcript expression is also controlled by TTP. In contrast, the upregulation of IL-19 transcription in response to LPS was not affected by TTP at early time points, while the decrease in the transcript abundance over time appeared to be accelerated if TTP was present (Fig. 5d) . Hence, at least at later time points, the IL-19 transcript may also belong to the group of TTP-regulated transcripts. www.nature.com/scientificreports www.nature.com/scientificreports/ Reconstitution of impaired NFκB activation in macrophages lacking MK2 upon the additional deletion of MK3 is due to accelerated ubiquitination and decay of IκBβ. We previously demonstrated that in MK2 −/− BMDM, nuclear translocation of the p65 NFκB subunit was impaired due to enhanced expression of inhibitor of κB (IκB)β and increased binding of p65 to IκBβ 5 . This impaired activation of NFκB in MK2 −/− BMDM has been demonstrated to be due to the action of MK3 in the absence of MK2. Since regular activation of NFκB is required for IFN-β gene expression, impaired NFκB activation was considered to be responsible for the reduced transcript expression observed in cells that lack MK2 (Fig. 1b) .
However, a more detailed analysis of the time dependency of NFκB subunit p65 appearance in nuclear extracts (Figs 6a and S6a) and its accompanying disappearance from cytosolic lysates (Figs 6b and S6b) in wt and MK2
−/−

BMDM revealed that LPS-induced nuclear translocation of p65 is not completely abolished in MK2
−/− BMDM, but is diminished and delayed compared to that in wt BMDM. The additional deletion of MK3 in MK2/3 −/− BMDM contributed greatly to restoring the wild-type conditions with respect to the time course and extension of p65 nuclear translocation (Figs 6a,b and S6a,b) . Notably, inhibition of p38 MAPK using the small molecule compound SB203580 (Fig. 6c) as well as deletion of MK2 (MK2 −/− BMDM) or both MK2 and MK3 (MK2/3 −/− BMDM) (Fig. 6d,e) resulted in an increased abundance of IκBβ molecules, consistent with previous observations from our group 5 . This increased availability of IκBβ molecules is considered to be responsible for the diminished and delayed release and nuclear translocation of the NFκB p65 subunit in MK2
−/− and in MK2/3 −/− BMDM compared to the wild-type conditions. Thereby, the kinetics of the decay of IκBβ as well as the time course of the phosphorylation of IκBβ at serines 19 and 23 upon stimulation with LPS did not significantly differ between wt and MK2 −/− BMDM (Fig. 6d,f) . This pattern indicates that compared to wt BMDM, MK2 −/− BMDM exhibit increased IκBβ levels while the velocity of the decay of IκBβ remains equal to wild-type conditions. Interestingly, in accordance with the observation that in MK2/3 −/− BMDM, nuclear translocation of p65 in response to LPS treatment was almost restored to wild-type levels (Figs 6a and S6a), the velocity of LPS-triggered IκBβ decay was substantially enhanced upon the additional deletion of MK3 in MK2/3 −/− BMDM compared to that in wt and IκBβ and for (g,h) , ubiquitin-ligated proteins were precipitated with polyubiquitin (PU) affinity beads and subjected to immunoblot analysis using antibodies specifically recognizing IκBβ, with a molecular weight of 50 kDa, or ubiquitinated proteins, from which the (2019) 9:11021 | https://doi.org/10.1038/s41598-019-46791-8 www.nature.com/scientificreports www.nature.com/scientificreports/
MK2
−/− BMDM, resulting in accelerated disappearance of IκBβ (Fig. 6d,f) . It is therefore suggested that the restoration of the nuclear translocation of p65 to wild-type levels upon the additional deletion of MK3 in MK2/3 −/− BMDM is due to an enhancement in the decay of IκBβ molecules in these cells (Fig. 6d,f) that otherwise would bind p65 5 and prevent its nuclear translocation. This enhancement was not accompanied by stronger or more prolonged Ser19/23 phosphorylation of IκBβ in MK2/3 −/− BMDM (Fig. 6d) . In line with the increased velocity of IκBβ molecule decay, evidence is provided that compared to wild-type and MK2
−/− BMDM, MK2/3 −/− BMDM exhibit earlier ubiquitination of IκBβ (Figs 6g and S6c) and that this ubiquitination can be reduced to wild-type or MK2
−/− levels if MK3 is reintroduced (Figs 6h and S6d) . Hence, in the absence of MK2, MK3 is responsible for delayed IκBβ ubiquitination. Our data suggest that the LPS-induced release of NFκB from IκBβ as well as the retention of NFκB in the cytosol by binding to IκBβ is controlled by the interplay of MK2 and MK3. In this case, MK2 suppresses the enhanced accumulation of IκBβ in the cytosol, whereas MK3 delays IκBβ ubiquitination and subsequent degradation to maintain temporally controlled LPS-induced NFκB release.
Discussion
Previous reports demonstrated that MK2 and MK3 control the expression of several mediators of inflammation, such as TNF-α, CXCL2 and IL-10, in a cooperative manner 5, 9 . Previous reports further suggested that MK2 and MK3 may also display distinct and, in part, contradictory regulatory effects on gene expression 5, 20 . Hence, as outlined above in macrophages, MK2 upregulates the transcription of IFN-β by neutralizing the negative regulatory effects of MK3, which impedes nuclear translocation of NFκB in the absence of MK2 5 . Correspondingly, as shown previously 5 and confirmed herein, the expression of IFN-β mRNA is lower in MK2 −/− BMDM than in wild-type BMDM, an effect that at least in part can be neutralized by the additional deletion of MK3, as seen in MK2/3 −/− BMDM (Fig. 1b) . Notably, deletion of MK3 alone in MK3 −/− BMDM had no effect on the LPS-inducible expression of IFN-β, indicating that MK3 exerts its negative regulatory effects on IFN-β gene expression only in the absence of MK2 (Supplemental Fig. S1b ). This behavior is in contrast to the LPS-inducible expression of IL-10, which was downregulated in MK2 −/− as well as in MK2/3 −/− BMDM (Fig. 1a) and tended to be reduced also in MK3 −/− BMDM (Supplemental Fig. S1a ) compared with that in wild-type BMDM. This finding supports recent observations that the regulation of IL-10 expression is governed by MK2 in cooperation with MK3 5, 9 . A major aim of the present study was to clarify whether MK2 also controls the LPS-inducible expression of genes other than IFN-β by neutralizing the inhibitory effects of MK3 on gene expression. As outlined above, we defined a group of genes (group III in Figs 3 and S4 ) regulated by the interplay of MK2 and MK3 in a similar way as IFN-β that, among others, includes the acute phase protein and serine peptidase inhibitor (Serpin)a3f and the pathogen recognition receptor Nod1 as well as the serine protease and component of the complement system C1rA (Fig. 4a-c) . As with the IFN-β gene (Fig. 1b) , the LPS-inducible expression of these genes was significantly diminished in BMDM lacking MK2 compared to that in wild-type control BMDM but was reconstituted or even enhanced upon the additional deletion of MK3 (Fig. 4a-c) . These data suggest that as it does for the IFN-β gene, MK3 negatively affects the expression of these genes in the absence of MK2, which neutralizes the negative regulatory effects of MK3. Of note, as it is the case for IFN-β gene expression, deletion of MK3 alone in MK3 −/− BMDM does not affect the LPS-inducible expression of these genes, indicating that the negative regulatory effect of MK3 only becomes apparent in the absence of MK2 (Supplemental Fig. S5a-c) . Contrariwise, the LPS-inducible expression of genes summarized herein as group I (Fig. 3) , including genes such as the chemokine CXCL2, the IL-4 receptor subunit (IL-4R)α and the cytokine IL-19 ( Fig. 4d-f ) is strongly impaired in MK2 −/− macrophages, an effect, which at least in part tends to be further enhanced upon additional deletion of MK3. Consistently, the data presented herein suggest that, although not significant, the LPS-inducible expression of these genes also tends to be impaired in the absence of MK3 (Supplemental Fig. S5d-f ). This type of regulation corresponds to that noted in previous reports demonstrating that MK2 and MK3 cooperate in upregulating the biosynthesis of genes such as IL-10 and TNF-α 5, 9 . Further studies as well as the results shown in Fig. 5 demonstrate that the transcripts of these genes are targets of the RNA-binding protein TTP [13] [14] [15] 19, 21 . These findings suggest that at least some of the genes in group I are also target genes of TTP.
Notably, the data presented herein suggest that in BMDM, the regulation of gene expression by the interplay of MK2 and MK3 in response to LPS is far more complex than the two regulatory patterns summarized as group I, or Il10-type, and group III, or Ifnb1-type. Hence, at least four additional regulatory patterns were identified based on the alteration of LPS-inducible gene expression in BMDM in response to deletion of MK2 or both MK2 and MK3 (Figs 3 and S4) . These patterns suggest that in addition to cooperatively upregulating gene expression or neutralizing the negative regulatory effects of MK3, MK2 may either cooperate with MK3 to limit the upregulation of gene expression in response to LPS, as demonstrated for IL-12 subunit b (Fig. 4g , group II or Il12b-type), or counteract the enhancing effects of MK3, as demonstrated for CXCL3 (Fig. 4h , group IV or Cxcl3-type). In the latter case, gene expression was strongly enhanced in MK2 −/− BMDM compared with that in wild-type control cells, and this enhancement was reversed upon the additional deletion of MK3. In addition, as validated herein for the genes HDC (Fig. 4i) and CXCL9 (Fig. 4j) , there are two groups -termed herein as groups V and VI (Figs 3 fraction containing proteins with a maximum molecular weight of 25 kDa is shown. (a-d,g,h) show samples from the same experiment, and the juxtaposed images show detections from different areas of the same blot or from the same area of different blots with the same samples, if the proteins of interest had approximately the same molecular weight. To set the focus on the individual antibody signals, images were cropped at the borders depicted with a black line. The time kinetics of IκBβ expression following LPS treatment shown in d were examined via densitometric analysis with n = 3 replicates, and data are presented as the means ± SEMs (e,f), demonstrating the basal expression (e) or time-dependent degradation of IκBβ (f). Statistics were calculated as described in the methods section; the following symbols indicate significance: *) wt vs. . These observations indicate that in some cases, MK2 and MK3 may thoroughly compensate for each other, whereas deletion of both causes drastic effects by unbalancing the cellular response to LPS. The underlying molecular mechanisms of the complex interplay by which the two kinases MK2 and MK3 achieve these different mechanisms of regulation of gene expression in response to LPS is largely unclear and must be the subject of future research.
However, in this context, it is interesting to note that the negative regulatory effects of MK3 on IFN-β gene expression in the absence of MK2 are caused by delayed release of NFκB from its complex with IκBβ 5 . Consistent with this observation, compared to wild-type controls, MK2
−/− BMDM exhibited impaired LPS-inducible nuclear translocation of the NFκB complex p65 subunit (Figs 6a and S6a), coinciding with prolonged detectability of p65 in the cytoplasm (Figs 6b and S6b). As suggested by previous data from immortalized BMDM cell lines, this delayed activation of NFκB in MK2 −/− BMDM is due to increased expression of the IκBβ protein in the absence of MK2 5 . The latter observation was confirmed herein for primary BMDM, where IκBβ expression is also increased in cells lacking MK2 (Fig. 6d,e) .
The data presented indicate that upon additional deletion of MK3 in MK2/3 −/− BMDM, NFκB activation is reconstituted in these cells, although the basal IκBβ levels are increased due to an accelerated decay of IκBβ (Fig. 6d,f) . Thereby, as demonstrated herein for the first time, in the absence of MK2, MK3 delays ubiquitination and subsequent degradation of IκBβ. This delay is circumvented upon additional MK3 deletion in MK2/3 −/− BMDM. Consistently, reconstitution of MK3 expression in MK2/3 −/− BMDM resulted in delayed IκBβ ubiquitination, which substantiates the hypothesis that MK3 is indeed responsible for hindering the degradation of IκBβ upon MK2 deficiency (Figs 6h and S6d). Hence, we suggest that in BMDM lacking MK2 p65 translocation is delayed due to an increased abundance of IκBβ protein in the cytoplasm and a MK3-mediated delay of their ubiquitination resulting in a prolonged degradation of IκBβ. The molecular mechanism by which MK3 interferes with the ubiquitination and degradation of IκBβ in the absence of MK2 is unclear and remains to be established. However, in this context it may be interesting to note that previous work indicates that activation of MK2 is interlinked with regulation of ubiquitination. Hence, the endoplasmic reticulum-associated ubiquitin-conjugating enzyme Ube2j1 has been demonstrated to be a substrate of MK2 and MK2-dependent signaling 23 and may be involved in the regulation of proteasomal degradation of the ARE-mRNA decay factor AUF1 24 .
Methods
Preparation and cultivation of murine bone marrow-derived macrophages. The establishment, genotyping, and colony maintenance of mice deficient for MK2 or for MK3 have been described elsewhere 25, 26 . Wild-type bone marrow-derived macrophages (wt BMDM), MK2-deficient BMDM (MK2 −/− BMDM) and BMDM deficient in MK2 and 3 (MK2/3 −/− BMDM) were prepared and cultivated as recently described 12 . The prepared BMDM were 96.7% (±3.6) F4/80-positive, 99.9% (±1.0) CD11b-positive and 71.3% (±2.5) CD11c-negative as assessed by flow cytometry analysis. The medium was changed to M-CSF-free culture medium 1 h before experiments were performed. Cells were used after a total differentiation period of 9 days. For experiments with immortalized murine bone marrow-derived macrophages (BMDM IM ), cells described previously were used 5, 12 .
Animals. The MK2-, MK3-and MK2/3-deficient animals on a C57BL/6J background have been previously described 9, 22, 26 . Animals were handled and housed under specific pathogen-free (SPF) conditions. Experiments were carried out in accordance with the German law for animal protection and were approved by the North-Rhine-Westphalia State Agency of Nature, Environment and Consumer Protection (LANUV) under the reference number 84-02.04.2013.A464.
RNA isolation and real-time PCR. RNA isolation and rtPCR were performed as described previously 5 . The primers used are listed in Supplemental Table 1 . The rtPCR specificity was controlled using controls lacking either template or reverse transcriptase. Semi-quantitative PCR results were analyzed using the ΔCT method, and the threshold values were normalized to the expression of hnSDHA.
Preparation of total cell lysates, cytosolic lysates and nuclear extracts. The preparation of total cell lysates, cytosolic lysates (CL) and nuclear extracts (NE) from murine immortalized or primary BMDM, respectively, was performed as described previously 5 .
Immunoblotting, immunoprecipitation and immunodetection. A total of 60 µg of protein extracts from cell culture lysates were subjected to SDS gel electrophoresis (8% PAA) and immunoblotted as described previously 5 . For immunodetection, the following primary antibodies were used at a 1:2,000 dilution: rabbit pol- No. H86504M, Meridian Life Science, Memphis, TN). The immunoprecipitation protocol has been described previously 5 . For the precipitation of polyubiquitinated proteins, a ubiquitinated protein enrichment kit (Cat. No. 662200, Merck, Darmstadt, Germany) was used according to the manufacturer's instructions.
